Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/STAT3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/STAT3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/STAT3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAT3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAT3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/STAT3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAT3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/STAT3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAT3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAT3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009199 | Colorectum | AD | ribonucleoside triphosphate metabolic process | 40/3918 | 89/18723 | 3.04e-07 | 1.21e-05 | 40 |
GO:0009152 | Colorectum | AD | purine ribonucleotide biosynthetic process | 64/3918 | 169/18723 | 3.09e-07 | 1.22e-05 | 64 |
GO:0009206 | Colorectum | AD | purine ribonucleoside triphosphate biosynthetic process | 33/3918 | 68/18723 | 3.68e-07 | 1.43e-05 | 33 |
GO:0007006 | Colorectum | AD | mitochondrial membrane organization | 48/3918 | 116/18723 | 4.53e-07 | 1.72e-05 | 48 |
GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
GO:0034101 | Colorectum | AD | erythrocyte homeostasis | 51/3918 | 129/18723 | 1.07e-06 | 3.59e-05 | 51 |
GO:0070997 | Colorectum | AD | neuron death | 114/3918 | 361/18723 | 1.13e-06 | 3.72e-05 | 114 |
GO:0009201 | Colorectum | AD | ribonucleoside triphosphate biosynthetic process | 34/3918 | 74/18723 | 1.23e-06 | 4.01e-05 | 34 |
GO:0030099 | Colorectum | AD | myeloid cell differentiation | 119/3918 | 381/18723 | 1.24e-06 | 4.01e-05 | 119 |
GO:0009260 | Colorectum | AD | ribonucleotide biosynthetic process | 66/3918 | 182/18723 | 1.25e-06 | 4.02e-05 | 66 |
GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
GO:0009132 | Colorectum | AD | nucleoside diphosphate metabolic process | 49/3918 | 124/18723 | 1.75e-06 | 5.31e-05 | 49 |
GO:0046939 | Colorectum | AD | nucleotide phosphorylation | 42/3918 | 101/18723 | 1.99e-06 | 5.92e-05 | 42 |
GO:0009142 | Colorectum | AD | nucleoside triphosphate biosynthetic process | 37/3918 | 85/18723 | 2.16e-06 | 6.35e-05 | 37 |
GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
GO:0034504 | Colorectum | AD | protein localization to nucleus | 94/3918 | 290/18723 | 2.83e-06 | 8.09e-05 | 94 |
GO:0046390 | Colorectum | AD | ribose phosphate biosynthetic process | 67/3918 | 190/18723 | 3.21e-06 | 9.05e-05 | 67 |
GO:0030522 | Colorectum | AD | intracellular receptor signaling pathway | 87/3918 | 265/18723 | 3.69e-06 | 1.03e-04 | 87 |
GO:0052547 | Colorectum | AD | regulation of peptidase activity | 137/3918 | 461/18723 | 4.12e-06 | 1.12e-04 | 137 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0514514 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
hsa052128 | Cervix | CC | Pancreatic cancer | 24/1267 | 76/8465 | 1.89e-04 | 1.11e-03 | 6.55e-04 | 24 |
hsa052234 | Cervix | CC | Non-small cell lung cancer | 21/1267 | 72/8465 | 1.48e-03 | 6.32e-03 | 3.74e-03 | 21 |
hsa046596 | Cervix | CC | Th17 cell differentiation | 28/1267 | 108/8465 | 1.99e-03 | 7.98e-03 | 4.72e-03 | 28 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa0406618 | Cervix | CC | HIF-1 signaling pathway | 27/1267 | 109/8465 | 4.72e-03 | 1.64e-02 | 9.72e-03 | 27 |
hsa049336 | Cervix | CC | AGE-RAGE signaling pathway in diabetic complications | 25/1267 | 100/8465 | 5.64e-03 | 1.88e-02 | 1.11e-02 | 25 |
hsa049172 | Cervix | CC | Prolactin signaling pathway | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
STAT3 | TREG | Endometrium | ADJ | GNA12,STAT5B,TNFRSF9, etc. | 6.57e-02 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
STAT3 | TREG | Endometrium | AEH | GNA12,STAT5B,TNFRSF9, etc. | 1.64e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_AEH/regulons_activity_in_dotplot.png) |
STAT3 | CD8TEREX | Endometrium | AEH | GNA12,STAT5B,TNFRSF9, etc. | 1.21e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_AEH/regulons_activity_in_dotplot.png) |
STAT3 | TREG | Endometrium | EEC | GNA12,STAT5B,TNFRSF9, etc. | 1.34e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_EEC/regulons_activity_in_dotplot.png) |
STAT3 | CD8TEREX | Endometrium | EEC | GNA12,STAT5B,TNFRSF9, etc. | 2.12e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Endometrium/Str/TF_EEC/regulons_activity_in_dotplot.png) |
STAT3 | STM | Esophagus | ESCC | ALDH9A1,MALAT1,ETV6, etc. | 4.44e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Esophagus/Str/TF_ESCC/regulons_activity_in_dotplot.png) |
STAT3 | CD8TEXINT | Lung | ADJ | SLC2A3,CRYBG1,RAPGEF6, etc. | 1.13e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Lung/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
STAT3 | CD8TEXP | Lung | ADJ | SLC2A3,CRYBG1,RAPGEF6, etc. | 1.21e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Lung/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
STAT3 | MDSC | Lung | Healthy | TAPBP,RSPH3,WARS, etc. | 8.71e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Lung/Str/TF_Healthy/regulons_activity_in_dotplot.png) |
STAT3 | MAIT | Oral cavity | NEOLP | HBP1,DPY19L1,VPS37B, etc. | 1.89e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/OralCavity/Str/TF_NEOLP/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAT3 | SNV | Missense_Mutation | novel | c.28C>G | p.Leu10Val | p.L10V | P40763 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
STAT3 | SNV | Missense_Mutation | | c.2171N>C | p.Leu724Pro | p.L724P | P40763 | protein_coding | tolerated(0.13) | possibly_damaging(0.641) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT3 | SNV | Missense_Mutation | novel | c.1692N>T | p.Trp564Cys | p.W564C | P40763 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-AC-A8OS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT3 | SNV | Missense_Mutation | | c.1229N>G | p.His410Arg | p.H410R | P40763 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
STAT3 | SNV | Missense_Mutation | rs113994137 | c.1268N>A | p.Arg423Gln | p.R423Q | P40763 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-BH-A0B0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
STAT3 | SNV | Missense_Mutation | | c.1855G>C | p.Val619Leu | p.V619L | P40763 | protein_coding | deleterious(0) | benign(0.029) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
STAT3 | SNV | Missense_Mutation | | c.1151T>A | p.Phe384Tyr | p.F384Y | P40763 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STAT3 | SNV | Missense_Mutation | | c.364N>A | p.Ala122Thr | p.A122T | P40763 | protein_coding | tolerated(0.59) | benign(0.006) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
STAT3 | SNV | Missense_Mutation | | c.1907N>T | p.Ser636Phe | p.S636F | P40763 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
STAT3 | SNV | Missense_Mutation | novel | c.934C>A | p.Leu312Met | p.L312M | P40763 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | NICLOSAMIDE | NICLOSAMIDE | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | Gold-complexed thiosaccharide derivative 3 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | Platinum IV complexe 1 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | GNF-PF-1399 | CHEMBL578504 | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | Salicylic acid derivative 3 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | Peptide analog 7 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | CELECOXIB | CELECOXIB | 21678971 |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | TAK-114 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | Salicylic acid derivative 1 | | |
6774 | STAT3 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, KINASE | | AZD-1480 | AZD-1480 | 21138246,24978112 |